Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor

The clinical prognostic factors during treatment are very important in chronic myeloid leukemia. An early molecular response and the halving time of BCR-ABL1 might be highly predictive of the outcome. A retrospective analysis of a cohort of 50 patients showed the importance of a very early molecular response in identifying subjects with favorable outcomes, using ABL1 as the control gene for the analysis.

Source: Clinical Lymphoma, Myeloma and Leukemia - March 31, 2016 Category: Hematology Authors: Carmen Fava, Giovanna Rege-Cambrin, Irene Dogliotti, Enrico Gottardi, Paola Berchialla, Bruno Di Gioacchino, Francesca Crasto, Roberta Lorenzatti, Alessandro Volpengo, Filomena Daraio, Cristina Fantino, Giuseppe Saglio Tags: SOHO Supplement 2016 Source Type: research